{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:39:11Z","timestamp":1785411551448,"version":"3.56.0"},"reference-count":395,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["No. 2020R1A6A1A03044512"],"award-info":[{"award-number":["No. 2020R1A6A1A03044512"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"award":["No. 2020R1A6A1A03044512"],"award-info":[{"award-number":["No. 2020R1A6A1A03044512"]}],"id":[{"id":"https:\/\/ror.org\/013aysd81","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Immunobiologics or biologics have revolutionized the therapeutic paradigm of autoimmune and inflammatory diseases by selectively targeting and modulating dysregulated immune pathways. Compared with conventional broad-spectrum immunosuppressants, biologics provide a more specific and mechanism-based rational approach, often associated with improved efficacy and reduced adverse events. This review provides a comprehensive overview of the repertoire of therapeutic biologics, their mechanisms of action, pivotal clinical trials, and clinical applications. We discuss biologics targeting T-cell activation, depletion, and adhesion, as well as agents neutralizing pro-inflammatory cytokines, including tumor necrosis factor (TNF), interleukin (IL)-1, IL-6, IL-12, IL-17, IL-22, and IL-23, in addition to B-cell-directed therapies and IgE-modulating agents. Evidence from randomized clinical trials and observational studies highlights the profound therapeutic impact of these agents across a broad spectrum of immune-mediated diseases, including rheumatoid arthritis, psoriasis, systemic lupus erythematosus (SLE), ankylosing spondylitis, chronic spontaneous urticaria, asthma, ulcerative colitis, Crohn\u2019s disease, and other forms of inflammatory bowel disease (IBD). Pharmacodynamic parameters, including receptor-binding affinity and downstream pathway modulation, are critical determinants of therapeutic efficacy, whereas pharmacovigilance remains indispensable for monitoring risks such as immunogenicity, opportunistic infections, and manufacturing-related variability. Continuous regulatory oversight by agencies such as the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) safeguards standards of safety, efficacy, and quality. In parallel, the expanding development of biosimilars offers a key opportunity to enhance affordability and broaden global access to biologic therapies. Despite substantial clinical progress, important challenges persist, including disease heterogeneity, variability in therapeutic response, long-term safety concerns, and issues of cost-effectiveness. Future directions emphasize precision medicine strategies, including biomarker-guided treatment, rationally designed biologic combinations, next-generation antibody engineering, and the development of high-quality biosimilars to improve therapeutic durability, safety, and accessibility equity. By integrating mechanistic insights with clinical outcomes, this review underscores the transformative role of immunobiologics and delineates strategies to optimize their application in the management of autoimmune and inflammatory diseases.<\/jats:p>","DOI":"10.3390\/pharmaceutics18080917","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T16:11:56Z","timestamp":1785168716000},"page":"917","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic Applications of Immunobiologics in Autoimmune and Inflammatory Diseases"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2789-5556","authenticated-orcid":false,"given":"Kannan Badri","family":"Narayanan","sequence":"first","affiliation":[{"name":"School of Chemical Engineering, Yeungnam University, 280 Daehak-Ro, Gyeongsan 38541, Gyeongsangbuk-do, Republic of Korea"},{"name":"Research Institute of Cell Culture, Yeungnam University, 280 Daehak-Ro, Gyeongsan 38541, Gyeongsangbuk-do, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e70262","DOI":"10.1002\/mco2.70262","article-title":"Autoimmune Diseases: Molecular Pathogenesis and Therapeutic Targets","volume":"6","author":"Song","year":"2025","journal-title":"MedComm"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2174\/1871530323666230915112642","article-title":"Autoimmune responses and therapeutic interventions for systemic lupus erythematosus: A comprehensive review","volume":"24","author":"Pandey","year":"2024","journal-title":"Endocr. Metab. Immune Disord.-Drug Targets"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41581-023-00720-1","article-title":"Pathogenesis of autoimmune disease","volume":"19","author":"Pisetsky","year":"2023","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s10495-014-1073-1","article-title":"Toll\/interleukin-1 receptor (TIR) domain-mediated cellular signaling pathways","volume":"20","author":"Narayanan","year":"2015","journal-title":"Apoptosis"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.smim.2017.08.010","article-title":"Drug nanocarriers to treat autoimmunity and chronic inflammatory diseases","volume":"34","author":"Prosperi","year":"2017","journal-title":"Semin. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Li, H., Yang, Y.-G., and Sun, T. (2022). Nanoparticle-based drug delivery systems for induction of tolerance and treatment of autoimmune diseases. Front. Bioeng. Biotechnol., 10.","DOI":"10.3389\/fbioe.2022.889291"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1016\/j.lpm.2011.01.005","article-title":"Pathophysiology of inflammatory and autoimmune myopathies","volume":"40","author":"Dalakas","year":"2011","journal-title":"LA Presse M\u00e9dicale"},{"key":"ref_8","first-page":"CD013562","article-title":"Disease-modifying anti-rheumatic drugs for rheumatoid arthritis: A systematic review and network meta-analysis","volume":"2020","author":"Hazlewood","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1126\/science.1099896","article-title":"Immune therapy for autoimmune diseases","volume":"305","author":"Steinman","year":"2004","journal-title":"Science"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"103612","DOI":"10.1016\/j.drudis.2023.103612","article-title":"Novel therapeutic strategies for autoimmune and inflammatory rheumatic diseases","volume":"28","author":"Felten","year":"2023","journal-title":"Drug Discov. Today"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Paluch, C., Santos, A.M., Anzilotti, C., Cornall, R.J., and Davis, S.J. (2018). Immune checkpoints as therapeutic targets in autoimmunity. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.02306"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.4110\/in.2022.22.e9","article-title":"Targeted immunotherapy for autoimmune disease","volume":"22","author":"Jung","year":"2022","journal-title":"Immune Netw."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Puca, P., Capobianco, I., Coppola, G., Di Vincenzo, F., Trapani, V., Petito, V., Laterza, L., Pugliese, D., Lopetuso, L.R., and Scaldaferri, F. (2024). Cellular and molecular determinants of biologic drugs resistance and therapeutic failure in inflammatory bowel disease. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25052789"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Fu, Y., Feng, C., Qin, S., Xing, Z., Liu, C., Liu, Z., and Yu, H. (2024). Breaking barriers: Advancing cellular therapies in autoimmune disease management. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1503099"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.2174\/138161212802502170","article-title":"Modern therapeutic strategies for autoimmune diseases","volume":"18","author":"Tyndall","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s43141-021-00264-6","article-title":"Hybridoma technology; advancements, clinical significance, and future aspects","volume":"19","author":"Mitra","year":"2021","journal-title":"J. Genet. Eng. Biotechnol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Baumgart, D.C., Misery, L., Naeyaert, S., and Taylor, P.C. (2019). Biological therapies in immune-mediated inflammatory diseases: Can biosimilars reduce access inequities?. Front. Pharmacol., 10.","DOI":"10.3389\/fphar.2019.00279"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Rosman, Z., Shoenfeld, Y., and Zandman-Goddard, G. (2013). Biologic therapy for autoimmune diseases: An update. BMC Med., 11.","DOI":"10.1186\/1741-7015-11-88"},{"key":"ref_19","first-page":"251","article-title":"Advanced combination treatment with biologic agents and novel small molecule drugs for inflammatory bowel disease","volume":"19","author":"Solitano","year":"2023","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1172\/JCI78088","article-title":"Mechanisms of human autoimmunity","volume":"125","author":"Rosenblum","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Yasmeen, F., Pirzada, R.H., Ahmad, B., Choi, B., and Choi, S. (2024). Understanding autoimmunity: Mechanisms, predisposing factors, and cytokine therapies. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25147666"},{"key":"ref_22","unstructured":"World Health Organization (2024). WHO Guideline on the Prevention and Diagnosis of Rheumatic Fever and Rheumatic Heart Disease, World Health Organization."},{"key":"ref_23","first-page":"72","article-title":"Influence of environmental factors in the development and outcomes of inflammatory bowel disease","volume":"15","author":"Vedamurthy","year":"2019","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(13)60954-X","article-title":"Immunopathogenic mechanisms of systemic autoimmune disease","volume":"382","year":"2013","journal-title":"Lancet"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1093\/carcin\/bgv032","article-title":"Disruptive environmental chemicals and cellular mechanisms that confer resistance to cell death","volume":"36","author":"Narayanan","year":"2015","journal-title":"Carcinogenesis"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13223-018-0278-1","article-title":"An introduction to immunology and immunopathology","volume":"14","author":"Marshall","year":"2018","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"ref_27","unstructured":"Busuttil, R.W., and Klintmalm, G.B. (2015). Long-term toxicity of immunosuppressive therapy. Transplantation of the Liver, Elsevier. [3rd ed.]."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1161\/CIRCRESAHA.120.315937","article-title":"Interleukin-1 and the inflammasome as therapeutic targets in cardiovascular disease","volume":"126","author":"Abbate","year":"2020","journal-title":"Circ. Res."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Kany, S., Vollrath, J.T., and Relja, B. (2019). Cytokines in inflammatory disease. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20236008"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"117177","DOI":"10.1016\/j.biopha.2024.117177","article-title":"The interplay between cytokines, inflammation, and antioxidants: Mechanistic insights and therapeutic potentials of various antioxidants and anti-cytokine compounds","volume":"178","author":"Bhol","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"ref_31","first-page":"167","article-title":"Update on treatment of psoriatic arthritis","volume":"70","author":"Mease","year":"2012","journal-title":"Bull. NYU Hosp. Jt. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Sagris, M., Theofilis, P., Antonopoulos, A.S., Oikonomou, E., Paschaliori, C., Galiatsatos, N., Tsioufis, K., and Tousoulis, D. (2021). Inflammation in coronary microvascular dysfunction. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222413471"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Narayanan, K.B. (2025). Enzyme-based anti-inflammatory therapeutics for inflammatory diseases. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17050606"},{"key":"ref_34","first-page":"107","article-title":"Biologics: The role of delivery systems in improved therapy","volume":"8","year":"2014","journal-title":"Biol. Targets Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1038\/s41467-023-38039-x","article-title":"Engineering protein-based therapeutics through structural and chemical design","volume":"14","author":"Ebrahimi","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.yexcr.2011.02.013","article-title":"Introduction to current and future protein therapeutics: A protein engineering perspective","volume":"317","author":"Carter","year":"2011","journal-title":"Exp. Cell Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1208\/s12248-023-00873-8","article-title":"Therapeutic fusion proteins","volume":"26","author":"Marsh","year":"2023","journal-title":"AAPS J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s13205-024-03958-z","article-title":"Therapeutic proteins: Developments, progress, challenges, and future perspectives","volume":"14","author":"Kumar","year":"2024","journal-title":"3 Biotech"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"989","DOI":"10.2174\/138161206776055930","article-title":"Biologicals dramatic advances in the treatment of psoriasis","volume":"12","author":"Martin","year":"2006","journal-title":"Curr. Pharm. Des."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/08830180701798976","article-title":"T-Cell\u2013Targeted Signaling Inhibitors","volume":"27","author":"Won","year":"2008","journal-title":"Int. Rev. Immunol."},{"key":"ref_41","first-page":"187","article-title":"International Nonproprietary Names (INN)","volume":"32","author":"Authorities","year":"2018","journal-title":"WHO Drug Inf."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.biologicals.2019.05.006","article-title":"The INN global nomenclature of biological medicines: A continuous challenge","volume":"60","author":"Robertson","year":"2019","journal-title":"Biologicals"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s10875-012-9794-9","article-title":"Introducing the Revised WEBbook of Biologics","volume":"32","author":"Eisenberg","year":"2012","journal-title":"J. Clin. Immunol."},{"key":"ref_44","unstructured":"Detrick, B., Schmitz, J.L., and Hamilton, R.G. (2020). Manual of Molecular and Clinical Laboratory Immunology, John Wiley & Sons."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2075078","DOI":"10.1080\/19420862.2022.2075078","article-title":"International nonproprietary names for monoclonal antibodies: An evolving nomenclature system","volume":"14","author":"Thorpe","year":"2022","journal-title":"mAbs"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1385\/MB:21:3:259","article-title":"Immunoglobulin fusion proteins as a tool for evaluation of T-cell costimulatory molecules","volume":"21","author":"Chapoval","year":"2002","journal-title":"Mol. Biotechnol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1002\/emmm.201201379","article-title":"Fc-fusion proteins: New developments and future perspectives","volume":"4","author":"Czajkowsky","year":"2012","journal-title":"EMBO Mol. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"384","DOI":"10.4161\/mabs.23976","article-title":"Immune suppression in cynomolgus monkeys by XPro9523: An improved CTLA4-Ig fusion with enhanced binding to CD80, CD86 and neonatal Fc receptor FcRn","volume":"5","author":"Bernett","year":"2013","journal-title":"mAbs"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-6632.2009.05382.x","article-title":"An overview of cytokines and cytokine antagonists as therapeutic agents","volume":"1182","author":"Donnelly","year":"2009","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1177\/0271678X15620204","article-title":"Recombinant human interleukin-1 receptor antagonist promotes M1 microglia biased cytokines and chemokines following human traumatic brain injury","volume":"36","author":"Helmy","year":"2016","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/nbt1142","article-title":"Engineered antibody fragments and the rise of single domains","volume":"23","author":"Holliger","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Pirkalkhoran, S., Grabowska, W.R., Kashkoli, H.H., Mirhassani, R., Guiliano, D., Dolphin, C., and Khalili, H. (2023). Bioengineering of antibody fragments: Challenges and opportunities. Bioengineering, 10.","DOI":"10.3390\/bioengineering10020122"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3899\/jrheum.120257","article-title":"The inhibitor of costimulation of T cells: Abatacept","volume":"89","author":"Iannone","year":"2012","journal-title":"J. Rheumatol. Suppl."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"108515","DOI":"10.1016\/j.clim.2020.108515","article-title":"The IL-2\u2013IL-2 receptor pathway in health and disease: The role of the soluble IL-2 receptor","volume":"218","author":"Damoiseaux","year":"2020","journal-title":"Clin. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1742-7843.2009.00375.x","article-title":"Abatacept, a novel CD80\/86\u2013CD28 T cell co-stimulation modulator, in the treatment of rheumatoid arthritis","volume":"104","author":"Korhonen","year":"2009","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_56","first-page":"61","article-title":"Abatacept in the treatment of polyarticular JIA: Development, clinical utility, and place in therapy","volume":"5","author":"Goldzweig","year":"2011","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jpeds.2011.11.057","article-title":"Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis","volume":"160","author":"Arabshahi","year":"2012","journal-title":"J. Pediatr."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3534104","DOI":"10.1155\/2024\/3534104","article-title":"Abatacept: A Promising Repurposed Solution for Myocardial Infarction-Induced Inflammation in Rat Models","volume":"2024","author":"Verma","year":"2024","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.atherosclerosis.2021.09.024","article-title":"Targeting cytokines and immune checkpoints in atherosclerosis with monoclonal antibodies","volume":"335","author":"Lutgens","year":"2021","journal-title":"Atherosclerosis"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1177\/19458924211072364","article-title":"Abatacept (Cytotoxic T Lymphocyte Antigen 4-Fragment Crystallizable) Reduces Allergic Inflammation of Ovalbumin-Sensitized Mice","volume":"36","author":"Chung","year":"2022","journal-title":"Am. J. Rhinol. Allergy"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1080\/14397595.2018.1467257","article-title":"Current diagnosis and treatment of polymyositis and dermatomyositis","volume":"28","author":"Sasaki","year":"2018","journal-title":"Mod. Rheumatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"14680","DOI":"10.1038\/ncomms14680","article-title":"T cell costimulation blockade blunts pressure overload-induced heart failure","volume":"8","author":"Kallikourdis","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13075-017-1309-x","article-title":"Interleukin-10-producing LAG3+ regulatory T cells are associated with disease activity and abatacept treatment in rheumatoid arthritis","volume":"19","author":"Nakachi","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13075-018-1527-x","article-title":"Abatacept blocks anti-citrullinated protein antibody and rheumatoid factor mediated cytokine production in human macrophages in IDO-dependent manner","volume":"20","author":"Bozec","year":"2018","journal-title":"Arthritis Res. Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/nyas.13643","article-title":"CTLA-4Ig (abatacept) balances bone anabolic effects of T cells and Wnt-10b with antianabolic effects of osteoblastic sclerostin","volume":"1415","author":"Vikulina","year":"2018","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_67","first-page":"500","article-title":"Effects of combined treatments with CTLA4-IG (abatacept), dexamethasone and methotrexate on cultured human macrophages","volume":"34","author":"Cutolo","year":"2016","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Almogairen, S.M. (2019). Abatacept induced granulomatous hepatitis with a sarcoidosis-like reaction: A blinded trial in mice. BMC Pharmacol. Toxicol., 20.","DOI":"10.1186\/s40360-019-0303-0"},{"key":"ref_69","first-page":"373","article-title":"Basiliximab, mechanism of action and pharmacological properties","volume":"58","author":"Kapic","year":"2004","journal-title":"Med. Arh."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Chen, T., Li, X., Wang, J., Wang, X., Zhu, T., Rong, R., and Yang, C. (2022). Basiliximab for the therapy of acute T cell\u2013mediated rejection in kidney transplant recipient with BK virus infection: A case report. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1017872"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1517\/14656566.3.11.1657","article-title":"The use of basiliximab in solid organ transplantation","volume":"3","author":"Henry","year":"2002","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1517\/14712598.7.1.137","article-title":"The role of basiliximab induction therapy in organ transplantation","volume":"7","author":"Ramirez","year":"2007","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Cohan, S.L., Lucassen, E.B., Romba, M.C., and Linch, S.N. (2019). Daclizumab: Mechanisms of action, therapeutic efficacy, adverse events and its uncovering the potential role of innate immune system recruitment as a treatment strategy for relapsing multiple sclerosis. Biomedicines, 7.","DOI":"10.3390\/biomedicines7010018"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.1365-2133.2001.03991.x","article-title":"Treatment of recalcitrant psoriasis with daclizumab","volume":"144","author":"Wohlrab","year":"2001","journal-title":"Br. J. Dermatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"D963","DOI":"10.1093\/nar\/gky963","article-title":"DrugCentral 2018: An update","volume":"47","author":"Ursu","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/icb.2017.6","article-title":"Antibody-dependent cell cytotoxicity: Immunotherapy strategies enhancing effector NK cells","volume":"95","author":"Ochoa","year":"2017","journal-title":"Immunol. Cell Biol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12575-025-00265-6","article-title":"Mechanisms of T-cell Depletion in Tumors and Advances in Clinical Research","volume":"27","author":"Su","year":"2025","journal-title":"Biol. Proced. Online"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/intimm\/1.2.169","article-title":"The role of CD2\/LFA-3 interaction in antigen-and mitogen-induced activation of human T cells","volume":"1","author":"Tiefenthaler","year":"1989","journal-title":"Int. Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/ddr.20468","article-title":"T-cell targeted therapies in autoimmune diseases","volume":"72","author":"Alnaimat","year":"2011","journal-title":"Drug Dev. Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.4049\/jimmunol.1801449","article-title":"Soluble Fc-Disabled Herpes Virus Entry Mediator Augments Activation and Cytotoxicity of NK Cells by Promoting Cross-Talk between NK Cells and Monocytes","volume":"202","author":"Meng","year":"2019","journal-title":"J. Immunol."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Baldo, B.A. (2016). Fusion Proteins. Safety of Biologics Therapy: Monoclonal Antibodies, Cytokines, Fusion Proteins, Hormones, Enzymes, Coagulation Proteins, Vaccines, Botulinum Toxins, Springer.","DOI":"10.1007\/978-3-319-30472-4"},{"key":"ref_82","first-page":"608","article-title":"Alefacept. Biogen","volume":"4","author":"Ormerod","year":"2003","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00403-006-0716-7","article-title":"Explorative immunohistochemical study to evaluate the addition of a topical corticosteroid in the early phase of alefacept treatment for psoriasis","volume":"298","author":"Bovenschen","year":"2007","journal-title":"Arch. Dermatol. Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/BF03325637","article-title":"Treatment of psoriasis and psoriatic arthritis","volume":"27","author":"Papoutsaki","year":"2013","journal-title":"BioDrugs"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1038\/jid.2013.78","article-title":"Which antipsoriatic drug has the fastest onset of action?\u2014Systematic review on the rapidity of the onset of action","volume":"133","author":"Nast","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1046\/j.1365-2230.2002.01171.x","article-title":"Treatment targeted to cell surface epitopes","volume":"27","author":"Mrowietz","year":"2002","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0952-7915(01)00279-5","article-title":"Therapeutic intervention with inhibitors of co-stimulatory pathways in autoimmune disease","volume":"13","author":"Aruffo","year":"2001","journal-title":"Curr. Opin. Immunol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1177\/1756283X10373176","article-title":"Anti-adhesion molecule therapy for inflammatory bowel disease","volume":"3","author":"Ghosh","year":"2010","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/cei\/uxad093","article-title":"Targeting T-cell integrins in autoimmune and inflammatory diseases","volume":"215","author":"Kelly","year":"2024","journal-title":"Clin. Exp. Immunol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.2310\/7750.2009.00023","article-title":"Safety of conventional systemic agents and biologic agents in the treatment of psoriasis","volume":"13","author":"Bissonnette","year":"2009","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_91","first-page":"14","article-title":"The status of biologic therapies in the treatment of moderate to severe psoriasis","volume":"84","author":"Menter","year":"2009","journal-title":"Cutis"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0966-3274(02)00029-1","article-title":"Anti-adhesion antibodies: Efalizumab, a humanized anti-CD11a monoclonal antibody","volume":"9","author":"Dedrick","year":"2002","journal-title":"Transpl. Immunol."},{"key":"ref_93","first-page":"301","article-title":"Efalizumab in the treatment of psoriasis","volume":"1","author":"Boehncke","year":"2007","journal-title":"Biol. Targets Ther."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Lichnog, C., Klabunde, S., Becker, E., Fuh, F., Tripal, P., Atreya, R., Klenske, E., Erickson, R., Chiu, H., and Reed, C. (2019). Cellular mechanisms of etrolizumab treatment in inflammatory bowel disease. Front. Pharmacol., 10.","DOI":"10.3389\/fphar.2019.00039"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1007\/s12325-020-01366-2","article-title":"Etrolizumab for the treatment of ulcerative colitis and Crohn\u2019s disease: An overview of the phase 3 clinical program","volume":"37","author":"Sandborn","year":"2020","journal-title":"Adv. Ther."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0065-2776(08)60022-X","article-title":"Lymphocyte trafficking and regional immunity","volume":"72","author":"Butcher","year":"1999","journal-title":"Adv. Immunol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1084\/jem.194.9.1243","article-title":"Intestinal mast cell progenitors require CD49d\u03b27 (\u03b14\u03b27 integrin) for tissue-specific homing","volume":"194","author":"Gurish","year":"2001","journal-title":"J. Exp. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1111\/j.1476-5381.2011.01205.x","article-title":"A humanized monoclonal antibody targeting the \u03b27 integrin selectively blocks intestinal homing of T lymphocytes","volume":"162","author":"Stefanich","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1083\/jcb.140.1.197","article-title":"Direct and regulated interaction of integrin \u03b1E\u03b27 with E-cadherin","volume":"140","author":"Higgins","year":"1998","journal-title":"J. Cell Biol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1136\/gutjnl-2011-301769","article-title":"A randomised phase I study of etrolizumab (rhuMAb \u03b27) in moderate to severe ulcerative colitis","volume":"62","author":"Rutgeerts","year":"2013","journal-title":"Gut"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(14)60661-9","article-title":"Etrolizumab as induction therapy for ulcerative colitis: A randomised, controlled, phase 2 trial","volume":"384","author":"Vermeire","year":"2014","journal-title":"Lancet"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(21)00338-1","article-title":"Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): Two phase 3 randomised, controlled trials","volume":"7","author":"Rubin","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_103","unstructured":"Genentech (2026, July 23). Genentech Provides Update on Phase III Studies of Etrolizumab in People with Moderately to Severely Active Ulcerative Colitis. Available online: https:\/\/www.gene.com\/media\/press-releases\/14870\/2020-08-09\/genentech-provides-update-on-phase-iii-s."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus interferon beta-1a for relapsing multiple sclerosis","volume":"354","author":"Rudick","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Gubatan, J., Keyashian, K., Rubin, S.J., Wang, J., Buckman, C.A., and Sinha, S. (2021). Anti-integrins for the treatment of inflammatory bowel disease: Current evidence and perspectives. Clin. Exp. Gastroenterol., 333\u2013342.","DOI":"10.2147\/CEG.S293272"},{"key":"ref_108","unstructured":"FDA News Release (2025, October 01). FDA Approves First Biosimilar to Treat Multiple Sclerosis, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-biosimilar-treat-multiple-sclerosis."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1177\/2040622315586970","article-title":"Vedolizumab: An \u03b14\u03b27 integrin antagonist for ulcerative colitis and Crohn\u2019s disease","volume":"6","author":"Cherry","year":"2015","journal-title":"Ther. Adv. Chronic Dis."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1053\/j.gastro.2014.05.008","article-title":"Effects of vedolizumab induction therapy for patients with Crohn\u2019s disease in whom tumor necrosis factor antagonist treatment failed","volume":"147","author":"Sands","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s12026-021-09173-9","article-title":"Effect of interleukin-6,-17,-21,-22, and-23 and STAT3 on signal transduction pathways and their inhibition in autoimmune arthritis","volume":"69","author":"Tabarkiewicz","year":"2021","journal-title":"Immunol. Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/1744666X.2026.2625277","article-title":"Targeting cytokine pathways: The role of biologics in autoinflammatory disorders","volume":"22","author":"Koga","year":"2026","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/j.jaad.2006.07.019","article-title":"Off-label uses of biologics in dermatology: Rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2)","volume":"56","author":"Graves","year":"2007","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1529-8019.2008.00180.x","article-title":"From conventional to cutting edge: The new era of biologics in treatment of psoriasis","volume":"21","author":"Tzu","year":"2008","journal-title":"Dermatol. Ther."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cyto.2016.08.014","article-title":"Molecular mechanisms of action of anti-TNF-\u03b1 agents\u2013Comparison among therapeutic TNF-\u03b1 antagonists","volume":"101","author":"Mitoma","year":"2018","journal-title":"Cytokine"},{"key":"ref_118","first-page":"33","article-title":"The role of adalimumab in rheumatic and autoimmune disorders: Comparison with other biologic agents","volume":"4","author":"Reimold","year":"2012","journal-title":"Open Access Rheumatol. Res. Rev."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/nrd1182","article-title":"Fresh from the pipeline: Adalimumab","volume":"2","author":"Bain","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrd1109","article-title":"Therapeutic strategies for rheumatoid arthritis","volume":"2","author":"Smolen","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/ecco-jcc\/jjad167","article-title":"Adalimumab: A \u2018Maillon Faible\u2019 in the Treatment of Ulcerative Colitis?","volume":"18","author":"Roblin","year":"2024","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2147\/TCRM.S1265","article-title":"Treating psoriasis with adalimumab","volume":"4","author":"Alwawi","year":"2008","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1111\/jdv.12981","article-title":"Adalimumab in the treatment of moderate-to-severe chronic plaque psoriasis in patients switching from other biologics","volume":"29","author":"Sator","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s12328-017-0726-3","article-title":"Adalimumab therapy in a patient with Crohn\u2019s disease with a giant pelvic paraganglioma after chemotherapy","volume":"10","author":"Mizoshita","year":"2017","journal-title":"Clin. J. Gastroenterol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"e11053","DOI":"10.1097\/MD.0000000000011053","article-title":"Adalimumab therapy in hepatitis B virus-negative polyarteritis nodosa: A case report","volume":"97","author":"Wang","year":"2018","journal-title":"Medicine"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1097\/IAE.0000000000002281","article-title":"Adalimumab therapy for refractory birdshot chorioretinopathy","volume":"39","author":"Kuijpers","year":"2019","journal-title":"Retina"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/ced.14016","article-title":"Sporadic Blau syndrome treated with adalimumab","volume":"44","author":"Millington","year":"2019","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"123018","DOI":"10.1016\/j.jns.2024.123018","article-title":"Adalimumab as treatment for neurosarcoidosis: A case series","volume":"460","author":"Shen","year":"2024","journal-title":"J. Neurol. Sci."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1080\/09273948.2016.1236969","article-title":"Adalimumab treatment in patients with Vogt\u2013Koyanagi\u2013Harada disease","volume":"26","author":"Couto","year":"2018","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1111\/1756-185X.12421","article-title":"Adalimumab in the treatment of refractory adult-onset Still\u2019s disease","volume":"20","author":"Lee","year":"2017","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"e70002","DOI":"10.1002\/edm2.70002","article-title":"Adalimumab Treatment Effects on Inflammation and Adipose Tissue Mitochondrial Respiration in Hidradenitis Suppurativa","volume":"7","author":"Sahl","year":"2024","journal-title":"Endocrinol. Diabetes Metab."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"124","DOI":"10.2340\/00015555-2170","article-title":"Successful Treatment of Multicentric Reticulohistiocytosis with Adalimumab, Prednisolone and Methotrexate","volume":"96","author":"Motegi","year":"2016","journal-title":"Acta Derm.-Venereol."},{"key":"ref_133","first-page":"2288","article-title":"Adalimumab-induced remission of anterior scleritis: A very rare late manifestation of Takayasu arteritis","volume":"54","author":"Akhtar","year":"2015","journal-title":"Rheumatology"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/WNF.0000000000000518","article-title":"Evidence for anti-inflammatory effects of adalimumab in treatment of patients with major depressive disorder: A pilot, randomized, controlled trial","volume":"45","author":"Abbasian","year":"2022","journal-title":"Clin. Neuropharmacol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"116568","DOI":"10.1016\/j.biopha.2024.116568","article-title":"Effect of adalimumab as an anti-inflammatory agent on gene expression of retinal pigment epithelial cells","volume":"174","author":"Nowroozzadeh","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"ref_136","first-page":"15","article-title":"Review of Biosimilars of Adalimumab","volume":"65","author":"Kaushik","year":"2017","journal-title":"J. Assoc. Physicians India"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1586\/eci.10.69","article-title":"Certolizumab pegol: A new biologic targeting rheumatoid arthritis","volume":"6","author":"Patel","year":"2010","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2147\/nano.2007.2.1.3","article-title":"Targeting nanomedicines in the treatment of rheumatoid arthritis: Focus on certolizumab pegol","volume":"2","author":"Barnes","year":"2007","journal-title":"Int. J. Nanomed."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2165\/00063030-200822050-00005","article-title":"A PEGylated Fab\u2019fragment against tumor necrosis factor for the treatment of Crohn disease: Exploring a new mechanism of action","volume":"22","author":"Bourne","year":"2008","journal-title":"BioDrugs"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/j.1476-5381.2010.00702.x","article-title":"Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents","volume":"160","author":"Weger","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.2165\/00003495-200868100-00003","article-title":"Evidence-based therapy for cutaneous sarcoidosis","volume":"68","author":"Doherty","year":"2008","journal-title":"Drugs"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1396-0296.2004.04043.x","article-title":"Etanercept for the treatment of psoriasis and psoriatic arthritis","volume":"17","author":"Gottlieb","year":"2004","journal-title":"Dermatol. Ther."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa030409","article-title":"Etanercept as monotherapy in patients with psoriasis","volume":"349","author":"Leonardi","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/j.1365-2133.2011.10525.x","article-title":"The effect of systemic psoriasis therapies on the incidence of myocardial infarction: A cohort study","volume":"165","author":"Abuabara","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jaad.2008.11.898","article-title":"A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa","volume":"60","author":"Lee","year":"2009","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/j.1365-2133.2005.07067.x","article-title":"Etanercept: Effective in the management of hidradenitis suppurativa","volume":"154","author":"Cusack","year":"2006","journal-title":"Br. J. Dermatol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.det.2010.03.012","article-title":"Biologic drugs for the treatment of hidradenitis suppurativa: An evidence-based review","volume":"28","author":"Shuja","year":"2010","journal-title":"Dermatol. Clin."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/sj.eye.6703100","article-title":"Bilateral Candida chorioretinitis following etanercept treatment for hidradenitis suppurativa","volume":"22","year":"2008","journal-title":"Eye"},{"key":"ref_149","unstructured":"Johnson & Johnson (2025, October 01). News Details. SIMPONI\u00ae (Golimumab) Receives FDA Approval for Ulcerative Colitis. Available online: https:\/\/www.investor.jnj.com\/investor-news\/news-details\/2013\/SIMPONI-Golimumab-Receives-FDA-Approval-For-Ulcerative-Colitis-05-15-2013\/default.aspx."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.gtc.2006.09.001","article-title":"Treatment of immune-mediated extraintestinal manifestations of inflammatory bowel disease with infliximab","volume":"35","author":"Barrie","year":"2006","journal-title":"Gastroenterol. Clin."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1475705","DOI":"10.1155\/2019\/1475705","article-title":"Tenascin-C Is Increased in Inflammatory Bowel Disease and Is Associated with response to Infliximab Therapy","volume":"2019","author":"Ning","year":"2019","journal-title":"BioMed Res. Int."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1097\/MPG.0000000000001876","article-title":"Hyperadiponectinemia during infliximab induction therapy in pediatric Crohn disease","volume":"66","author":"Frivolt","year":"2018","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_153","first-page":"167","article-title":"Use of infliximab in treatment of acute pancreatitis","volume":"116","author":"Tekin","year":"2015","journal-title":"Bratisl. Lek. Listy"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s12016-015-8492-9","article-title":"Treatment of sarcoidosis","volume":"49","author":"Baughman","year":"2015","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"e176","DOI":"10.1097\/MD.0000000000000176","article-title":"Infliximab for peripheral ulcerative keratitis treatment","volume":"93","author":"Huerva","year":"2014","journal-title":"Medicine"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1080\/17843286.2018.1522020","article-title":"Beh\u00e7et\u2019s disease; A rare refractory patient with vena cava superior syndrome treated with infliximab: A case report and review of the literature","volume":"74","author":"Uyaroglu","year":"2019","journal-title":"Acta Clin. Belg."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12974-014-0172-9","article-title":"Infliximab reduces Zaprinast-induced retinal degeneration in cultures of porcine retina","volume":"11","author":"Salom","year":"2014","journal-title":"J. Neuroinflamm."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","article-title":"Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis","volume":"146","author":"Panaccione","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.jpeds.2014.01.020","article-title":"Infliximab plus plasma exchange rescue therapy in Kawasaki disease","volume":"164","author":"Sonoda","year":"2014","journal-title":"J. Pediatr."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"274","DOI":"10.15403\/jgld.2014.1121.243.bwp","article-title":"Infliximab therapy for corticosteroid-resistant ipilimumab-induced colitis","volume":"24","author":"Matkowskyj","year":"2015","journal-title":"J. Gastrointestin Liver Dis."},{"key":"ref_161","first-page":"e40812","article-title":"Infliximab-Induced Interstitial Pneumonitis: A Case Report","volume":"15","author":"Makkawy","year":"2023","journal-title":"Cureus"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/cei.12872","article-title":"Anti-inflammatory effects of infliximab in mice are independent of tumour necrosis factor \u03b1 neutralization","volume":"187","author":"Assas","year":"2017","journal-title":"Clin. Exp. Immunol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1208\/s12249-019-1308-0","article-title":"Respiratory administration of infliximab dry powder for local suppression of inflammation","volume":"20","author":"Faghihi","year":"2019","journal-title":"AAPS PharmSciTech"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1111\/jgh.14652","article-title":"ZNF133 is associated with infliximab responsiveness in patients with inflammatory bowel diseases","volume":"34","author":"Jung","year":"2019","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1136\/heartjnl-2015-308953","article-title":"Anti-inflammatory treatment improves high-density lipoprotein function in rheumatoid arthritis","volume":"103","author":"Charakida","year":"2017","journal-title":"Heart"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1080\/03009742.2023.2300887","article-title":"Anti-inflammatory effects of infliximab and methotrexate on peripheral blood and synovial fluid mononuclear cells: Ex vivo study","volume":"53","author":"Gertel","year":"2024","journal-title":"Scand. J. Rheumatol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.pharep.2016.05.008","article-title":"Pharmacology and metabolism of infliximab biosimilars\u2014A new treatment option in inflammatory bowel diseases","volume":"68","author":"Fichna","year":"2016","journal-title":"Pharmacol. Rep."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1080\/14712598.2019.1653848","article-title":"CT-P13: A review on a biosimilar to infliximab in the treatment of inflammatory bowel disease","volume":"19","author":"Albshesh","year":"2019","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.2217\/imt-2017-0068","article-title":"A review article on biosimilar infliximab SB2 in the treatment of rheumatoid arthritis","volume":"9","author":"Bellinvia","year":"2017","journal-title":"Immunotherapy"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/imr.12621","article-title":"Overview of the IL-1 family in innate inflammation and acquired immunity","volume":"281","author":"Dinarello","year":"2018","journal-title":"Immunol. Rev."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"e20190314","DOI":"10.1084\/jem.20190314","article-title":"Inflammasome signaling and regulation of interleukin-1 family cytokines","volume":"217","author":"Chan","year":"2019","journal-title":"J. Exp. Med."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"2503378","DOI":"10.1155\/2021\/2503378","article-title":"Interleukin-1 Links Autoimmune and Autoinflammatory Pathophysiology in Mixed-Pattern Psoriasis","volume":"2021","author":"Kobiec","year":"2021","journal-title":"Mediat. Inflamm."},{"key":"ref_173","unstructured":"Nigrovic, P.A. (2025, October 01). Interleukin 1 Inhibitors: Biology, Principles of Use, and Adverse Events. Available online: https:\/\/www.uptodate.com\/contents\/interleukin-1-inhibitors-biology-principles-of-use-and-adverse-events#H620493584."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2165\/00063030-200216040-00005","article-title":"Anakinra","volume":"16","author":"Cvetkovic","year":"2002","journal-title":"BioDrugs"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/nrd2947","article-title":"Rheumatoid arthritis market","volume":"8","author":"Stoll","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_176","first-page":"CD005121","article-title":"Anakinra for rheumatoid arthritis","volume":"2009","author":"Mertens","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1002\/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO;2-2","article-title":"Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist","volume":"41","author":"Bresnihan","year":"1998","journal-title":"Arthritis Rheum."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/art.1780390513","article-title":"Anticytokine treatment of established type II collagen\u2013induced arthritis in DBA\/1 mice: A comparative study using anti-TNF\u03b1, anti\u2013IL-1\u03b1\/\u03b2, and IL-1Ra","volume":"39","author":"Joosten","year":"1996","journal-title":"Arthritis Rheum."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1023\/A:1011903100188","article-title":"Effects of interleukin-1 receptor antagonist in a slow-release hylan vehicle on rat type II collagen arthritis","volume":"15","author":"Bendele","year":"1998","journal-title":"Pharm. Res."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/1529-0131(199904)42:3<498::AID-ANR15>3.0.CO;2-A","article-title":"Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: Comparison of efficacy in animal models with human clinical data","volume":"42","author":"Bendele","year":"1999","journal-title":"Arthritis Rheum."},{"key":"ref_181","first-page":"409","article-title":"Comparative efficacy of novel DMARDs as monotherapy and in combination with methotrexate in rheumatoid arthritis patients with inadequate response to conventional DMARDs: A network meta-analysis","volume":"21","author":"Buckley","year":"2015","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"90","DOI":"10.4274\/balkanmedj.2017.0111","article-title":"Juvenile idiopathic arthritis","volume":"34","author":"Barut","year":"2017","journal-title":"Balk. Med. J."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1093\/rheumatology\/40.1.62","article-title":"The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis","volume":"40","author":"Cunnane","year":"2001","journal-title":"Rheumatology"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1161\/01.ATV.20.11.2394","article-title":"Interleukin-1 receptor antagonist expression in human endothelial cells and atherosclerosis","volume":"20","author":"Dewberry","year":"2000","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1161\/ATVBAHA.112.300432","article-title":"Genetic and pharmacologic disruption of interleukin-1\u03b2 signaling inhibits experimental aortic aneurysm formation","volume":"33","author":"Johnston","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s00392-019-01443-9","article-title":"Differential effects of inhibition of interleukin 1 and 6 on myocardial, coronary and vascular function","volume":"108","author":"Ikonomidis","year":"2019","journal-title":"Clin. Res. Cardiol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"e28581","DOI":"10.1002\/pbc.28581","article-title":"The use of anakinra in the treatment of secondary hemophagocytic lymphohistiocytosis","volume":"67","author":"Bami","year":"2020","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"e277","DOI":"10.1111\/jdv.14022","article-title":"Severe osteoarticular involvement in isotretinoin-triggered acne fulminans: Two cases successfully treated with anakinra","volume":"31","author":"Oranges","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_189","doi-asserted-by":"crossref","unstructured":"Ferguson, P.J., and El-Shanti, H. (2021). Majeed Syndrome: A review of the clinical, genetic and immunologic features. Biomolecules, 11.","DOI":"10.3390\/biom11030367"},{"key":"ref_190","unstructured":"Adam, M.P., Bick, S., Mirzaa, G.M., Pagon, R.A., Wallace, S.E., and Amemiya, A. (2025, October 25). LPIN2-Related Majeed Syndrome, GeneReviews [Internet], Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK589480\/."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1111\/epi.13121","article-title":"A definition and classification of status epilepticus\u2013Report of the ILAE Task Force on Classification of Status Epilepticus","volume":"56","author":"Trinka","year":"2015","journal-title":"Epilepsia"},{"key":"ref_192","doi-asserted-by":"crossref","unstructured":"Foiadelli, T., Santangelo, A., Costagliola, G., Costa, E., Scacciati, M., Riva, A., Volpedo, G., Smaldone, M., Bonuccelli, A., and Clemente, A. (2023). Neuroinflammation and status epilepticus: A narrative review unraveling a complex interplay. Front. Pediatr., 11.","DOI":"10.3389\/fped.2023.1251914"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"e24434","DOI":"10.1002\/jcla.24434","article-title":"Anakinra treatment efficacy in reduction of inflammatory biomarkers in COVID-19 patients: A meta-analysis","volume":"36","author":"Naveed","year":"2022","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_194","first-page":"81","article-title":"Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders","volume":"11","author":"Church","year":"2009","journal-title":"Curr. Opin. Mol. Ther."},{"key":"ref_195","doi-asserted-by":"crossref","unstructured":"Dhimolea, E. (2010). Canakinumab. MAbs, Taylor & Francis.","DOI":"10.4161\/mabs.2.1.10328"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1365-2125.2011.03958.x","article-title":"Rilonacept and canakinumab","volume":"71","author":"Dubois","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/ar1908","article-title":"The inflammatory process of gout and its treatment","volume":"8","author":"Cronstein","year":"2006","journal-title":"Arthritis Res. Ther."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1136\/annrheumdis-2016-210352","article-title":"Renal dosing of allopurinol results in suboptimal gout care","volume":"76","author":"Neogi","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1517\/14712598.2012.705825","article-title":"Canakinumab in gout","volume":"12","author":"Schlesinger","year":"2012","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/j.clinthera.2014.08.004","article-title":"Pharmacokinetic and pharmacodynamic characteristics of single-dose canakinumab in patients with type 2 diabetes mellitus","volume":"36","author":"Noe","year":"2014","journal-title":"Clin. Ther."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1161\/CIRCULATIONAHA.112.122556","article-title":"Effects of interleukin-1\u03b2 inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: A phase IIb randomized, placebo-controlled trial","volume":"126","author":"Ridker","year":"2012","journal-title":"Circulation"},{"key":"ref_202","first-page":"4","article-title":"Atherosclerosis: Perspectives of anti-inflammatory therapy","volume":"90","author":"Nasonov","year":"2018","journal-title":"Ter. Arkhiv"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/FJC.0000000000000546","article-title":"Why the CANTOS is a game changer in cardiovascular medicine","volume":"70","author":"Abbate","year":"2017","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"38","DOI":"10.15420\/ecr.2018.11.1","article-title":"Role of anti-inflammatory interventions in coronary artery disease: Understanding the canakinumab anti-inflammatory thrombosis outcomes study (CANTOS)","volume":"13","author":"Lorenzatti","year":"2018","journal-title":"Eur. Cardiol. Rev."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1136\/heartjnl-2019-316481","article-title":"Acute recurrent pericarditis: From pathophysiology towards new treatment strategy","volume":"106","author":"Cacoub","year":"2020","journal-title":"Heart"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"e14857","DOI":"10.1111\/1756-185X.14857","article-title":"Long-term efficacy of canakinumab in hyperimmunoglobulin D syndrome","volume":"27","author":"Karadag","year":"2024","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1172\/JCI88884","article-title":"Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk","volume":"127","author":"Goldfine","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/ni.1935","article-title":"Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1\u03b2 in type 2 diabetes","volume":"11","author":"Masters","year":"2010","journal-title":"Nat. Immunol."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.2337\/dc12-1835","article-title":"Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1\u03b2 antibody, in patients with type 2 diabetes","volume":"36","author":"Polzer","year":"2013","journal-title":"Diabetes Care"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1016\/j.jacc.2018.03.002","article-title":"Anti-inflammatory therapy with canakinumab for the prevention and management of diabetes","volume":"71","author":"Everett","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.bbi.2023.10.012","article-title":"Adjunctive canakinumab reduces peripheral inflammation markers and improves positive symptoms in people with schizophrenia and inflammation: A randomized control trial","volume":"115","author":"Weickert","year":"2024","journal-title":"Brain Behav. Immun."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nrd.2017.186","article-title":"Anti-inflammatory drug cuts risk of heart disease--and cancer","volume":"16","author":"Dolgin","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"S3084","DOI":"10.21037\/jtd.2018.07.50","article-title":"Interleukin-1 beta inhibition with canakinumab and reducing lung cancer\u2014Subset analysis of the canakinumab anti-inflammatory thrombosis outcome study trial (CANTOS)","volume":"10","author":"Crossman","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1097\/CAD.0000000000000832","article-title":"A review of canakinumab and its therapeutic potential for non-small cell lung cancer","volume":"30","author":"Schenk","year":"2019","journal-title":"Anti-Cancer Drugs"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1200\/JCO.23.00910","article-title":"Canakinumab as adjuvant therapy in patients with completely resected non\u2013small-cell lung cancer: Results from the CANOPY-A double-blind, randomized clinical trial","volume":"42","author":"Garon","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_216","doi-asserted-by":"crossref","unstructured":"Lu\u00eds, J.P., Sim\u00f5es, C.J., and Brito, R.M. (2022). The therapeutic prospects of targeting IL-1R1 for the modulation of neuroinflammation in central nervous system disorders. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031731"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1007\/s00393-009-0542-3","article-title":"Empfehlungen zur Therapie mit Interleukin-1\u03b2-blockierenden Wirkstoffen","volume":"68","author":"Manger","year":"2009","journal-title":"Z. Rheumatol."},{"key":"ref_218","first-page":"29","article-title":"Tratamiento de los s\u00edndromes peri\u00f3dicos asociados a la criopirina (CAPS)","volume":"136","author":"Polo","year":"2011","journal-title":"Med. Cl\u00edn."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/pedi.12634","article-title":"A phase I study of anti-inflammatory therapy with rilonacept in adolescents and adults with type 1 diabetes mellitus","volume":"19","author":"White","year":"2018","journal-title":"Pediatr. Diabetes"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.jbspin.2015.02.009","article-title":"Rilonacept in the treatment of subacromial bursitis: A randomized, non-inferiority, unblinded study versus triamcinolone acetonide","volume":"82","author":"Carroll","year":"2015","journal-title":"Jt. Bone Spine"},{"key":"ref_221","first-page":"153","article-title":"Evaluation of rilonacept in patients with gouty arthritis experiencing an acute gout attack","volume":"62","author":"Terkeltaub","year":"2010","journal-title":"Arthritis Rheumatol."},{"key":"ref_222","first-page":"1227","article-title":"Inflamed colon and pericardium: A rare combination of colitis and recurrent pericarditis","volume":"3","author":"Kumar","year":"2021","journal-title":"Case Rep."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/FJC.0000000000001435","article-title":"Interleukin-1 blockers for the treatment of recurrent pericarditis: Pathophysiology, patient reported outcomes and perspectives","volume":"83","author":"Thomas","year":"2024","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"314","DOI":"10.23736\/S0031-0808.21.04263-4","article-title":"Pharmacologic treatment of acute and recurrent pericarditis: A systematic review and meta-analysis of controlled clinical trials","volume":"63","author":"Avondo","year":"2021","journal-title":"Panminerva Medica"},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s40256-021-00481-x","article-title":"A brief overview of recurrent pericarditis management and the potential of rilonacept as a new therapeutic option","volume":"22","author":"Gupta","year":"2021","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/CRD.0000000000000704","article-title":"Goflikicept and Related IL-1 Inhibitors in the Treatment of Recurrent Pericarditis","volume":"34","author":"Feldman","year":"2024","journal-title":"Cardiol. Rev."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-023-01620-3","article-title":"The IL-17 family in diseases: From bench to bedside","volume":"8","author":"Huangfu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"102429","DOI":"10.1016\/j.autrev.2019.102429","article-title":"Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies","volume":"19","author":"Puig","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.3390\/cimb44050127","article-title":"The treatment with interleukin 17 inhibitors and immune-mediated inflammatory diseases","volume":"44","author":"Bembea","year":"2022","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1358\/dot.2023.59.3.3419557","article-title":"Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis","volume":"59","author":"Simopoulou","year":"2023","journal-title":"Drugs Today"},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1056\/NEJMoa1109017","article-title":"Brodalumab, an anti\u2013interleukin-17\u2013receptor antibody for psoriasis","volume":"366","author":"Papp","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"ii43","DOI":"10.1093\/rheumatology\/kew346","article-title":"Effect of IL-17 receptor A blockade with brodalumab in inflammatory diseases","volume":"55","author":"Nirula","year":"2016","journal-title":"Rheumatology"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"132","DOI":"10.36849\/JDD.2020.4774","article-title":"Real-world clinical experience with the IL-17 receptor a antagonist brodalumab","volume":"19","author":"Bettencourt","year":"2020","journal-title":"J. Drugs Dermatol. JDD"},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1517\/14712598.2016.1132695","article-title":"Ixekizumab: A new anti-IL-17A monoclonal antibody therapy for moderate-to severe plaque psoriasis","volume":"16","author":"Blauvelt","year":"2016","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/14712598.2018.1410133","article-title":"Ixekizumab: An anti-IL-17A monoclonal antibody for the treatment of psoriatic arthritis","volume":"18","author":"Toussirot","year":"2018","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/ijd.70092","article-title":"Efficacy of Biologics for the Treatment of Moderate-to-Severe Plaque Psoriasis in the Asian Population: A Systematic Review and Network Meta-Analysis","volume":"65","author":"Asahina","year":"2025","journal-title":"Int. J. Dermatol."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/nrd3794","article-title":"Targeting IL-17 and TH17 cells in chronic inflammation","volume":"11","author":"Miossec","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000501991","article-title":"Secukinumab: The anti-IL-17a biologic for the treatment of psoriasis","volume":"11","author":"Fargnoli","year":"2019","journal-title":"Case Rep. Dermatol."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/2040622317738910","article-title":"Secukinumab: A review of the anti-IL-17A biologic for the treatment of psoriasis","volume":"9","author":"Frieder","year":"2018","journal-title":"Ther. Adv. Chronic Dis."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nm.3895","article-title":"IL-12 and IL-23 cytokines: From discovery to targeted therapies for immune-mediated inflammatory diseases","volume":"21","author":"Teng","year":"2015","journal-title":"Nat. Med."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41575-023-00768-1","article-title":"IL-12 and IL-23 pathway inhibition in inflammatory bowel disease","volume":"20","author":"Verstockt","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"100261","DOI":"10.1016\/j.xjidi.2024.100261","article-title":"Structural basis for p19 targeting by anti\u2013IL-23 biologics: Correlations with short-and long-term efficacy in psoriasis","volume":"4","author":"Daniele","year":"2024","journal-title":"JID Innov."},{"key":"ref_243","doi-asserted-by":"crossref","unstructured":"Krueger, J.G., Eyerich, K., Kuchroo, V.K., Ritchlin, C.T., Abreu, M.T., Elloso, M.M., Fourie, A., Fakharzadeh, S., Sherlock, J.P., and Yang, Y.-W. (2024). IL-23 past, present, and future: A roadmap to advancing IL-23 science and therapy. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1331217"},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2165\/11595940-000000000-00000","article-title":"Briakinumab for the treatment of plaque psoriasis","volume":"26","author":"Traczewski","year":"2012","journal-title":"BioDrugs"},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1001\/archdermatol.2007.63","article-title":"Safety and efficacy of ABT-874, a fully human interleukin 12\/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: Results of a randomized, placebo-controlled, phase 2 trial","volume":"144","author":"Kimball","year":"2008","journal-title":"Arch. Dermatol."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1517\/14712590903092188","article-title":"Briakinumab","volume":"9","author":"Lima","year":"2009","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jaad.2018.01.016","article-title":"Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial","volume":"78","author":"Brunner","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_248","doi-asserted-by":"crossref","unstructured":"Lo, Y., Cheng, T.-T., Huang, C.-J., Cheng, Y.-C., and Chyuan, I.-T. (2025). Advancing Therapeutic Strategies in Atopic Dermatitis: Emerging Targets and Personalized Approaches. Biomolecules, 15.","DOI":"10.3390\/biom15060838"},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"234","DOI":"10.5114\/reum.2019.87620","article-title":"Tildrakizumab in the treatment of psoriasis\u2013literature review","volume":"57","author":"Banaszczyk","year":"2019","journal-title":"Rheumatology"},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"903","DOI":"10.2147\/TCRM.S227880","article-title":"Tildrakizumab: An evidence-based review of its use in the treatment of moderate-to-severe chronic plaque psoriasis","volume":"16","author":"Zachariae","year":"2020","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_251","first-page":"147413","article-title":"Ustekinumab in psoriasis immunopathology with emphasis on the Th17-IL23 axis: A primer","volume":"2012","author":"Quatresooz","year":"2012","journal-title":"BioMed Res. Int."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"key":"ref_253","first-page":"853","article-title":"Sexy and 17: TH17 effector T cells and psoriasis","volume":"6","author":"Brownell","year":"2007","journal-title":"J. Drugs Dermatol. JDD"},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"a016295","DOI":"10.1101\/cshperspect.a016295","article-title":"IL-6 in inflammation, immunity, and disease","volume":"6","author":"Tanaka","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.12688\/f1000research.26058.1","article-title":"Interleukin-6 signalling in health and disease","volume":"9","year":"2020","journal-title":"F1000Research"},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.pharmthera.2013.09.004","article-title":"Targeting interleukin-6 in inflammatory autoimmune diseases and cancers","volume":"141","author":"Yao","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1186\/s13063-022-06897-3","article-title":"Clazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: Phase 3 IMAGINE study rationale and design","volume":"23","author":"Nickerson","year":"2022","journal-title":"Trials"},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1002\/art.39700","article-title":"The efficacy and safety of clazakizumab, an anti\u2013interleukin-6 monoclonal antibody, in a phase IIb study of adults with active psoriatic arthritis","volume":"68","author":"Mease","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"ref_259","unstructured":"Bristol-Myers Squibb (2025, October 01). Promising Phase IIb Data on Clazakizumab in Patients with Moderate-to-Severe Rheumatoid Arthritis to Be Presented at the 2013 Annual Meeting of the American College of Rheumatology. Available online: https:\/\/news.bms.com\/news\/details\/2013\/Promising-Phase-IIb-Data-On-Clazakizumab-In-Patients-With-Moderate-To-Severe-Rheumatoid-Arthritis-To-Be-Presented-At-The-2013-Annual-Meeting-Of-The-American-College-Of-Rheumatology\/default.aspx."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3324\/haematol.2016.145060","article-title":"Due to interleukin-6 type cytokine redundancy only glycoprotein 130 receptor blockade efficiently inhibits myeloma growth","volume":"102","author":"Burger","year":"2017","journal-title":"Haematologica"},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"100029","DOI":"10.1016\/j.cytox.2020.100029","article-title":"SARS-CoV-2 and COVID-19: Is interleukin-6 (IL-6) the \u2018culprit lesion\u2019of ARDS onset? What is there besides Tocilizumab? SGP130Fc","volume":"2","author":"Magro","year":"2020","journal-title":"Cytokine X"},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/annrheumdis-2021-219876","article-title":"Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: Efficacy and safety results of a randomised controlled phase III study","volume":"81","author":"Nasonov","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1136\/annrheumdis-2013-204405","article-title":"Sarilumab, a fully human monoclonal antibody against IL-6R\u03b1 in patients with rheumatoid arthritis and an inadequate response to methotrexate: Efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial","volume":"73","author":"Huizinga","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_264","unstructured":"Regeneron Pharmaceuticals, Inc. (PR Newswire, 2017). Regeneron and Sanofi Announce FDA Approval of Kevzara\u00ae (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients, PR Newswire."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2217\/imt.15.127","article-title":"Sarilumab for the treatment of rheumatoid arthritis","volume":"8","author":"Cooper","year":"2016","journal-title":"Immunotherapy"},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1002\/art.38091","article-title":"Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus","volume":"65","author":"Szepietowski","year":"2013","journal-title":"Arthritis Rheum."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.intimp.2015.04.049","article-title":"Upcoming biological therapies in systemic lupus erythematosus","volume":"27","author":"Sciascia","year":"2015","journal-title":"Int. Immunopharmacol."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"e001465","DOI":"10.1136\/rmdopen-2020-001465","article-title":"Long-term safety and efficacy of sirukumab for patients with rheumatoid arthritis who previously received sirukumab in randomised controlled trials (SIRROUND-LTE)","volume":"7","author":"Aletaha","year":"2021","journal-title":"RMD Open"},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.2147\/DDDT.S99898","article-title":"Spotlight on sirukumab for the treatment of rheumatoid arthritis: The evidence to date","volume":"10","author":"Lazzerini","year":"2016","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaut.2014.06.002","article-title":"Novel approaches to the development of targeted therapeutic agents for systemic lupus erythematosus","volume":"54","author":"Sthoeger","year":"2014","journal-title":"J. Autoimmun."},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1016\/j.febslet.2011.03.023","article-title":"Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases","volume":"585","author":"Tanaka","year":"2011","journal-title":"FEBS Lett."},{"key":"ref_272","doi-asserted-by":"crossref","unstructured":"Nishimoto, N., and Kishimoto, T. (2008). Humanized antihuman IL-6 receptor antibody, tocilizumab. Therapeutic Antibodies, Springer.","DOI":"10.1007\/978-3-540-73259-4_7"},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/ard.2008.092932","article-title":"IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: Results from a 24-week multicentre randomised placebo-controlled trial","volume":"67","author":"Emery","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1136\/ard.2006.068064","article-title":"Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab","volume":"66","author":"Nishimoto","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2008.092866","article-title":"Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): Evidence of safety and efficacy in a 5-year extension study","volume":"68","author":"Nishimoto","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1002\/art.22033","article-title":"Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate","volume":"54","author":"Maini","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"24071","DOI":"10.18632\/aging.203644","article-title":"LncRNA MIR31HG is induced by tocilizumab and ameliorates rheumatoid arthritis fibroblast-like synoviocyte-mediated inflammation via miR-214-PTEN-AKT signaling pathway","volume":"13","author":"Cao","year":"2021","journal-title":"Aging"},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1001\/jama.2022.15459","article-title":"Effect of tocilizumab on disease activity in patients with active polymyalgia rheumatica receiving glucocorticoid therapy: A randomized clinical trial","volume":"328","author":"Dernis","year":"2022","journal-title":"JAMA"},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"e38104","DOI":"10.1097\/MD.0000000000038104","article-title":"Tocilizumab in the treatment of hyperferritinemic syndrome and capillary leak syndrome secondary to rheumatoid arthritis: Case report and literature review","volume":"103","author":"He","year":"2024","journal-title":"Medicine"},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1007\/s10067-018-3992-7","article-title":"Tocilizumab reduces complement C3 and C4 serum levels in rheumatoid arthritis patients","volume":"37","author":"Romano","year":"2018","journal-title":"Clin. Rheumatol."},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"SII79","DOI":"10.3949\/ccjm.69.Suppl_2.SII79","article-title":"Epidemiology of giant-cell arteritis","volume":"69","author":"Hunder","year":"2002","journal-title":"Clevel. Clin. J. Med."},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(16)00560-2","article-title":"Tocilizumab for induction and maintenance of remission in giant cell arteritis: A phase 2, randomised, double-blind, placebo-controlled trial","volume":"387","author":"Villiger","year":"2016","journal-title":"Lancet"},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/09273948.2019.1617885","article-title":"Successful tocilizumab treatment for scleritis","volume":"28","author":"Poelman","year":"2020","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_284","first-page":"1512","article-title":"Possible immuno-modulatory effects of tocilizumab in patients with refractory status epilepticus","volume":"27","author":"Hegazy","year":"2023","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"e5952","DOI":"10.1002\/ccr3.5952","article-title":"Anti-inflammatory and immune-mediated therapy for a case of febrile infection-related epilepsy syndrome with rapid recurrence","volume":"10","author":"Kurimoto","year":"2022","journal-title":"Clin. Case Rep."},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/j.bbi.2010.12.019","article-title":"Transcriptional control of maladaptive and protective responses in alcoholics: A role of the NF-\u03baB system","volume":"25","author":"Yakovleva","year":"2011","journal-title":"Brain Behav. Immun."},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1007\/s13311-020-00893-8","article-title":"IL-6 receptor blockade by tocilizumab has anti-absence and anti-epileptogenic effects in the WAG\/Rij rat model of absence epilepsy","volume":"17","author":"Leo","year":"2020","journal-title":"Neurotherapeutics"},{"key":"ref_288","first-page":"S46","article-title":"Therapeutic blockade of interleukin-6 by tocilizumab in the management of AA amyloidosis and chronic inflammatory disorders: A case series and review of the literature","volume":"33","author":"Lane","year":"2015","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_289","doi-asserted-by":"crossref","unstructured":"Zisman, D., Safieh, M., Simanovich, E., Feld, J., Kinarty, A., Zisman, L., Gazitt, T., Haddad, A., Elias, M., and Rosner, I. (2021). Tocilizumab (TCZ) decreases angiogenesis in rheumatoid arthritis through its regulatory effect on miR-146a-5p and EMMPRIN\/CD147. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.739592"},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"959","DOI":"10.2217\/imt-2016-0020","article-title":"Immunotherapeutic implications of IL-6 blockade for cytokine storm","volume":"8","author":"Tanaka","year":"2016","journal-title":"Immunotherapy"},{"key":"ref_291","doi-asserted-by":"crossref","unstructured":"Akita, K., Isoda, K., Sato-Okabayashi, Y., Kadoguchi, T., Kitamura, K., Ohtomo, F., Shimada, K., and Daida, H. (2017). An interleukin-6 receptor antibody suppresses atherosclerosis in atherogenic mice. Front. Cardiovasc. Med., 4.","DOI":"10.3389\/fcvm.2017.00084"},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1161\/ATVBAHA.108.173658","article-title":"Carotid Atherosclerotic Plaques Stabilize After Stroke","volume":"29","author":"Peeters","year":"2009","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1161\/01.CIR.101.12.1372","article-title":"Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: Potential implications for inflammation and plaque instability","volume":"101","author":"Schieffer","year":"2000","journal-title":"Circulation"},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/cvr\/cvq078","article-title":"Antibody against interleukin-6 receptor attenuates left ventricular remodelling after myocardial infarction in mice","volume":"87","author":"Kobara","year":"2010","journal-title":"Cardiovasc. Res."},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1093\/eurheartj\/ehw171","article-title":"Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: A double-blind, randomized, placebo-controlled phase 2 trial","volume":"37","author":"Kleveland","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"10","DOI":"10.31083\/j.rcm2401010","article-title":"Anti-inflammatory therapy in coronary artery disease: Where do we stand?","volume":"24","author":"Rakocevic","year":"2023","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_297","first-page":"145","article-title":"A new alternative therapy in dermatology: Tocilizumab","volume":"35","author":"Kalkan","year":"2016","journal-title":"Cutan. Ocul. Toxicol."},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s10067-017-3672-z","article-title":"IL-6 blockade in the management of non-infectious uveitis","volume":"36","author":"Lopalco","year":"2017","journal-title":"Clin. Rheumatol."},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/JPER.20-0455","article-title":"Specific inhibition of IL-6 receptor attenuates inflammatory bone loss in experimental periodontitis","volume":"92","author":"Vieira","year":"2021","journal-title":"J. Periodontol."},{"key":"ref_300","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejphar.2016.03.028","article-title":"Modulation of human monocyte\/macrophage activity by tocilizumab, abatacept and etanercept: An in vitro study","volume":"780","author":"Obeng","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/ckj\/sfac036","article-title":"Decreased chronic kidney disease in rheumatoid arthritis in the era of biologic disease-modifying anti-rheumatic drugs","volume":"15","author":"Hanaoka","year":"2022","journal-title":"Clin. Kidney J."},{"key":"ref_302","doi-asserted-by":"crossref","first-page":"102442","DOI":"10.1016\/j.jaut.2020.102442","article-title":"Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy","volume":"109","author":"Ceribelli","year":"2020","journal-title":"J. Autoimmun."},{"key":"ref_303","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s40249-021-00857-w","article-title":"Tocilizumab treatment for COVID-19 patients: A systematic review and meta-analysis","volume":"10","author":"Wei","year":"2021","journal-title":"Infect. Dis. Poverty"},{"key":"ref_304","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s10875-020-00774-x","article-title":"BCG-related inflammatory syndromes in severe combined immunodeficiency after TCR\u03b1\u03b2+\/CD19+ depleted HSCT","volume":"40","author":"Laberko","year":"2020","journal-title":"J. Clin. Immunol."},{"key":"ref_305","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s13075-015-0651-0","article-title":"The preclinical pharmacology of the high affinity anti-IL-6R Nanobody\u00ae ALX-0061 supports its clinical development in rheumatoid arthritis","volume":"17","author":"Ververken","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"ref_306","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1136\/annrheumdis-2017-eular.3746","article-title":"FRI0239 Results of a phase 2b study of vobarilizumab, an anti-interleukin-6 receptor nanobody, as monotherapy in patients with moderate to severe rheumatoid arthritis","volume":"76","author":"Weinblatt","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_307","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.1093\/cvr\/cvab231","article-title":"From RESCUE to ZEUS: Will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction?","volume":"117","author":"Ridker","year":"2021","journal-title":"Cardiovasc. Res."},{"key":"ref_308","unstructured":"(2025, October 01). Drug Profile Ziltivekimab\u2014Novo Nordisk. Available online: https:\/\/adisinsight.springer.com\/drugs\/800045660#:~:text=Thank%20you-,Ziltivekimab%20%2D%20Novo%20Nordisk,included%20in%20your%20email%20receipt."},{"key":"ref_309","unstructured":"(2025, October 01). ClinicalTrials.gov ID: NCT01559103. Study to Assess the Safety and Tolerability of MEDI5117 in Rheumatoid Arthritis Patients, Available online: https:\/\/clinicaltrials.gov\/study\/NCT01559103."},{"key":"ref_310","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1681\/ASN.2020050595","article-title":"Ziltivekimab for treatment of anemia of inflammation in patients on hemodialysis: Results from a phase 1\/2 multicenter, randomized, double-blind, placebo-controlled trial","volume":"32","author":"Pergola","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_311","unstructured":"(2025, October 01). ClinicalTrials.gov ID: NCT03926117. Trial to Evaluate Reduction in Inflammation in Patients with Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition (RESCUE), Available online: https:\/\/clinicaltrials.gov\/study\/NCT03926117."},{"key":"ref_312","unstructured":"(2025, October 01). ClinicalTrials.gov ID: NCT05021835. ZEUS\u2014A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People with Cardiovascular Disease, Chronic Kidney Disease and Inflammation (ZEUS), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05021835."},{"key":"ref_313","doi-asserted-by":"crossref","unstructured":"Giri, S., and Batra, L. (2025). Memory Cells in Infection and Autoimmunity: Mechanisms, Functions, and Therapeutic Implications. Vaccines, 13.","DOI":"10.3390\/vaccines13020205"},{"key":"ref_314","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1517\/14712598.2010.524923","article-title":"Targeting B cells with biologics in systemic lupus erythematosus","volume":"10","year":"2010","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_315","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2147\/JIR.S9425","article-title":"Current and emerging strategies for the treatment and management of systemic lupus erythematosus based on molecular signatures of acute and chronic inflammation","volume":"3","author":"Das","year":"2010","journal-title":"J. Inflamm. Res."},{"key":"ref_316","doi-asserted-by":"crossref","first-page":"6306","DOI":"10.2174\/1381612822666160831103254","article-title":"A review of clinical trials of belimumab in the management of systemic lupus erythematosus","volume":"22","author":"Garcia","year":"2016","journal-title":"Curr. Pharm. Des."},{"key":"ref_317","doi-asserted-by":"crossref","unstructured":"Regola, F., Piantoni, S., Lowin, T., Archetti, S., Reggia, R., Kumar, R., Franceschini, F., Air\u00f2, P., Tincani, A., and Andreoli, L. (2019). Association between changes in BLyS levels and the composition of B and T cell compartments in patients with refractory systemic lupus erythematosus treated with belimumab. Front. Pharmacol., 10.","DOI":"10.3389\/fphar.2019.00433"},{"key":"ref_318","doi-asserted-by":"crossref","first-page":"71","DOI":"10.4103\/0976-500X.155482","article-title":"Efficacy of novel monoclonal antibody belimumab in the treatment of lupus nephritis","volume":"6","author":"Frieri","year":"2015","journal-title":"J. Pharmacol. Pharmacother."},{"key":"ref_319","first-page":"190","article-title":"Belimumab, a BLyS-specific inhibitor, reduced disease activity, flares, and prednisone use in patients with seropositive SLE: Combined efficacy results from the phase 3 BLISS-52 and-76 studies","volume":"62","author":"Petri","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_320","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1080\/1744666X.2017.1291343","article-title":"Inhibition of B cell activating factor (BAFF) in the management of systemic lupus erythematosus (SLE)","volume":"13","author":"Stohl","year":"2017","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_321","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2174\/157015911796557984","article-title":"Neuropsychiatric systemic lupus erythematosus","volume":"9","author":"Popescu","year":"2011","journal-title":"Curr. Neuropharmacol."},{"key":"ref_322","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40265-018-0872-z","article-title":"Belimumab: A review in systemic lupus erythematosus","volume":"78","author":"Blair","year":"2018","journal-title":"Drugs"},{"key":"ref_323","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"ref_324","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum."},{"key":"ref_325","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1002\/art.24699","article-title":"A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus","volume":"61","author":"Wallace","year":"2009","journal-title":"Arthritis Care Res."},{"key":"ref_326","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1177\/0961203312465781","article-title":"Effect of belimumab treatment on renal outcomes: Results from the phase 3 belimumab clinical trials in patients with SLE","volume":"22","author":"Dooley","year":"2013","journal-title":"Lupus"},{"key":"ref_327","doi-asserted-by":"crossref","first-page":"2207671","DOI":"10.1080\/0886022X.2023.2207671","article-title":"Efficacy and safety of belimumab therapy in lupus nephritis: A systematic review and meta-analysis","volume":"45","author":"Zhang","year":"2023","journal-title":"Ren. Fail."},{"key":"ref_328","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1177\/09612033241233021","article-title":"Refractory lupus hepatitis successfully treated with telitacicept who failed to belimumab: A case report and literature review","volume":"33","author":"Fan","year":"2024","journal-title":"Lupus"},{"key":"ref_329","doi-asserted-by":"crossref","unstructured":"Xu, Y., Mo, Y., and Xu, Y. (2026). Advances in Novel Biologics Targeting BAFF\/APRIL in the Treatment of IgA Nephropathy. Cells, 15.","DOI":"10.3390\/cells15030240"},{"key":"ref_330","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.pharmthera.2010.01.001","article-title":"Targeting B cells in immune-mediated inflammatory disease: A comprehensive review of mechanisms of action and identification of biomarkers","volume":"125","author":"Kinnman","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"ref_331","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell\u2013targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_332","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1517\/13543784.17.1.31","article-title":"Systemic lupus erythematosus: Pharmacological developments and recommendations for a therapeutic strategy","volume":"17","author":"Isenberg","year":"2008","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_333","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1093\/rheumatology\/ker018","article-title":"The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: An evaluation","volume":"50","author":"Lu","year":"2011","journal-title":"Rheumatology"},{"key":"ref_334","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1177\/0961203309106174","article-title":"Rituximab in systemic lupus erythematosusA systematic review of off-label use in 188 cases","volume":"18","author":"Soto","year":"2009","journal-title":"Lupus"},{"key":"ref_335","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1177\/0961203310395802","article-title":"Assessment of flares in lupus patients enrolled in a phase II\/III study of rituximab (EXPLORER)","volume":"20","author":"Merrill","year":"2011","journal-title":"Lupus"},{"key":"ref_336","doi-asserted-by":"crossref","first-page":"R2","DOI":"10.1186\/ar4427","article-title":"Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis","volume":"16","author":"Kapetanovic","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"ref_337","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/j.jaci.2016.04.007","article-title":"Role of IgE in autoimmunity","volume":"137","author":"Sanjuan","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_338","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/nm.2755","article-title":"IgE and mast cells in allergic disease","volume":"18","author":"Galli","year":"2012","journal-title":"Nat. Med."},{"key":"ref_339","doi-asserted-by":"crossref","first-page":"e70024","DOI":"10.1111\/imr.70024","article-title":"IgE-Mediated Activation of Mast Cells and Basophils in Health and Disease","volume":"331","author":"Charles","year":"2025","journal-title":"Immunol. Rev."},{"key":"ref_340","doi-asserted-by":"crossref","unstructured":"Kothari, A., Hung, L., and Upton, J.E. (2025). Considerations for biologics as front-line treatment in allergic diseases. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1746790"},{"key":"ref_341","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/all.70061","article-title":"Biologics to treat atopic dermatitis: Effectiveness, Safety, and future directions","volume":"81","author":"Boesjes","year":"2026","journal-title":"Allergy"},{"key":"ref_342","first-page":"8163803","article-title":"IgE-related chronic diseases and anti-IgE-based treatments","volume":"2016","year":"2016","journal-title":"J. Immunol. Res."},{"key":"ref_343","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/imr.13380","article-title":"Therapeutic monoclonal antibodies in allergy: Targeting IgE, cytokine, and alarmin pathways","volume":"328","author":"Eggel","year":"2024","journal-title":"Immunol. Rev."},{"key":"ref_344","doi-asserted-by":"crossref","unstructured":"Domingo, C., Monserrate, D.R., Sogo, A., and Mirapeix, R.M. (2024). The incredible adventure of omalizumab. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25053056"},{"key":"ref_345","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1753466618810192","article-title":"Omalizumab, the first available antibody for biological treatment of severe asthma: More than a decade of real-life effectiveness","volume":"12","author":"Pelaia","year":"2018","journal-title":"Ther. Adv. Respir. Dis."},{"key":"ref_346","unstructured":"Novartis News (2025, October 21). Novartis Announces FDA Filing Acceptance of Xolair\u00ae (Omalizumab) for Treatment of Nasal Polyps. Available online: https:\/\/www.novartis.com\/us-en\/news\/media-releases\/novartis-announces-fda-filing-acceptance-xolair-omalizumab-treatment-nasal-polyps-0."},{"key":"ref_347","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s12325-016-0287-8","article-title":"Pharmacokinetics, pharmacodynamics, and safety of MEDI4212, an anti-IgE monoclonal antibody, in subjects with atopy: A phase I study","volume":"33","author":"Sheldon","year":"2016","journal-title":"Adv. Ther."},{"key":"ref_348","doi-asserted-by":"crossref","first-page":"755","DOI":"10.4161\/mabs.28394","article-title":"A novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthma","volume":"6","author":"Cohen","year":"2014","journal-title":"mAbs"},{"key":"ref_349","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12931-026-03501-z","article-title":"Effectiveness of biologics for reducing occlusive mucus plugs in patients with severe asthma: A systematic review","volume":"27","author":"Aegerter","year":"2026","journal-title":"Respir. Res."},{"key":"ref_350","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/cmi.2015.19","article-title":"Development of an antibody that neutralizes soluble IgE and eliminates IgE expressing B cells","volume":"13","author":"Nyborg","year":"2016","journal-title":"Cell. Mol. Immunol."},{"key":"ref_351","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41467-019-13815-w","article-title":"The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab","volume":"11","author":"Gasser","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_352","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/cea.12400","article-title":"Pharmacokinetics, pharmacodynamics and safety of QGE 031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects","volume":"44","author":"Arm","year":"2014","journal-title":"Clin. Exp. Allergy"},{"key":"ref_353","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0140-6736(23)01684-7","article-title":"Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: Results of two phase 3 randomised controlled trials","volume":"403","author":"Maurer","year":"2024","journal-title":"Lancet"},{"key":"ref_354","doi-asserted-by":"crossref","first-page":"e13982","DOI":"10.1111\/pai.13982","article-title":"Ligelizumab in adolescents with chronic spontaneous urticaria: Results of a dedicated phase 2b randomized clinical trial supported with pharmacometric analysis","volume":"34","author":"Staubach","year":"2023","journal-title":"Pediatr. Allergy Immunol."},{"key":"ref_355","unstructured":"(2025, October 21). ClinicalTrials.gov ID: NCT03580369. A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled with H1-Antihistamines, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03580369."},{"key":"ref_356","unstructured":"(2025, October 21). ClinicalTrials.gov ID: NCT03580356. A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled with H1-Antihistamines, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03580356."},{"key":"ref_357","unstructured":"Novartis News (2025, October 21). Novartis Ligelizumab (QGE031) Receives FDA Breakthrough Therapy Designation for Patients with Chronic Idiopathic Urticaria (CIU). Available online: https:\/\/www.novartis.com\/us-en\/news\/media-releases\/novartis-ligelizumab-qge031-receives-fda-breakthrough-therapy-designation-patients-chronic-idiopathic-urticaria-ciu."},{"key":"ref_358","doi-asserted-by":"crossref","first-page":"24","DOI":"10.2174\/22127038114019990003","article-title":"Quilizumab is an afucosylated humanized anti-M1 prime therapeutic antibody","volume":"1","author":"Brightbill","year":"2014","journal-title":"Clin. Anti-Inflamm. Anti-Allergy Drugs"},{"key":"ref_359","doi-asserted-by":"crossref","first-page":"243ra285","DOI":"10.1126\/scitranslmed.3008961","article-title":"Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production","volume":"6","author":"Gauvreau","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_360","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12931-016-0347-2","article-title":"A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma","volume":"17","author":"Harris","year":"2016","journal-title":"Respir. Res."},{"key":"ref_361","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1586\/1744666X.2015.1086645","article-title":"From IgE to clinical trials of allergic rhinitis","volume":"11","author":"Ciprandi","year":"2015","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_362","unstructured":"(2025, October 01). Drug Profile Quilizumab. Available online: https:\/\/adisinsight.springer.com\/drugs\/800032472?utm."},{"key":"ref_363","doi-asserted-by":"crossref","unstructured":"Jiang, Z., Zou, Y., Li, G., Zhao, S., and Zhang, W. (2024). Comparisons of infection events associated with tumor necrosis factor inhibitors in patients with inflammatory arthritis: A systematic review and network meta-analysis. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1376262"},{"key":"ref_364","doi-asserted-by":"crossref","first-page":"e2446336","DOI":"10.1001\/jamanetworkopen.2024.46336","article-title":"Use of biologic or targeted synthetic disease-modifying antirheumatic drugs and cancer risk","volume":"7","author":"Sendaydiego","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_365","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_366","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/S0140-6736(17)32247-X","article-title":"Effect of interleukin-1\u03b2 inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: Exploratory results from a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Ridker","year":"2017","journal-title":"Lancet"},{"key":"ref_367","unstructured":"Novartis (2026, July 23). Novartis Provides Update on Phase III CANOPY\u2014A Study Evaluating Canakinumab as Adjuvant Treatment in Non-Small Cell Lung Cancer. Available online: https:\/\/www.novartis.com\/news\/media-releases\/novartis-provides-update-phase-iii-canopy-study-evaluating-canakinumab-adjuvant-treatment-non-small-cell-lung-cancer."},{"key":"ref_368","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1136\/annrheumdis-2016-210297","article-title":"Low immunogenicity of tocilizumab in patients with rheumatoid arthritis","volume":"76","author":"Burmester","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_369","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jbspin.2016.04.013","article-title":"Immunogenicity of tocilizumab in patients with rheumatoid arthritis","volume":"84","author":"Sigaux","year":"2017","journal-title":"Jt. Bone Spine"},{"key":"ref_370","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1177\/1352458518792403","article-title":"A case of immune-mediated encephalitis related to daclizumab therapy","volume":"25","author":"Devlin","year":"2019","journal-title":"Mult. Scler. J."},{"key":"ref_371","unstructured":"Jeffrey, S. (Medscape Medical News, 2018). FDA Steps in to Manage Withdrawal of MS Drug Daclizumab (Zinbryta), Medscape Medical News."},{"key":"ref_372","doi-asserted-by":"crossref","first-page":"102320","DOI":"10.1016\/j.coph.2022.102320","article-title":"Pharmacological strategies for mitigating anti-TNF biologic immunogenicity in rheumatoid arthritis patients","volume":"68","author":"Fernandez","year":"2023","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_373","doi-asserted-by":"crossref","unstructured":"Alanazi, J., Aleanizy, F.S., and Alqahtani, F.Y. (2025). Nanotechnology Approaches for Mitigating Biologic Immunogenicity: A Literature Review. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17070888"},{"key":"ref_374","doi-asserted-by":"crossref","unstructured":"Naser-Tavakolian, A., Heard, J.R., and Ahdoot, M. (2025). Biologics. Translational Urology, Elsevier.","DOI":"10.1016\/B978-0-323-90186-4.00001-8"},{"key":"ref_375","doi-asserted-by":"crossref","first-page":"946","DOI":"10.3346\/jkms.2006.21.5.946","article-title":"Etanercept-induced systemic lupus erythematosus in a patient with rheumatoid arthritis","volume":"21","author":"Kang","year":"2006","journal-title":"J. Korean Med. Sci."},{"key":"ref_376","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1046\/j.1365-2230.2003.01411.x","article-title":"Etanercept-induced systemic lupus erythematosus","volume":"28","author":"Swale","year":"2003","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_377","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1212\/WNL.0b013e3182478d4b","article-title":"Fatal PML associated with efalizumab therapy: Insights into integrin \u03b1L\u03b22 in JC virus control","volume":"78","author":"Schwab","year":"2012","journal-title":"Neurology"},{"key":"ref_378","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1111\/j.1469-0691.2011.03653.x","article-title":"Progressive multifocal leukoencephalopathy: An unexpected complication of modern therapeutic monoclonal antibody therapies","volume":"17","author":"Tavazzi","year":"2011","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_379","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/ard-2024-225531","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update","volume":"83","author":"Gossec","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_380","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_381","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1053\/j.gastro.2021.04.022","article-title":"AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn\u2019s disease","volume":"160","author":"Feuerstein","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_382","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1093\/ecco-jcc\/jjae091","article-title":"ECCO guidelines on therapeutics in Crohn\u2019s disease: Medical treatment","volume":"18","author":"Gordon","year":"2024","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_383","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/art.41752","article-title":"2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_384","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1080\/21645515.2019.1591139","article-title":"A product review of vedolizumab in inflammatory bowel disease","volume":"15","author":"Battat","year":"2019","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_385","doi-asserted-by":"crossref","first-page":"e007393","DOI":"10.1161\/JAHA.117.007393","article-title":"Comparative cardiovascular risk of abatacept and tumor necrosis factor inhibitors in patients with rheumatoid arthritis with and without diabetes mellitus: A multidatabase cohort study","volume":"7","author":"Kang","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"ref_386","unstructured":"Johnson, J.A. (2025, October 21). Biologics and Biosimilars: Background and Key Issues. Available online: https:\/\/www.everycrsreport.com\/reports\/R44620.html."},{"key":"ref_387","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s40259-017-0256-z","article-title":"Biosimilarity and Interchangeability: Principles and Evidence: A Systematic Review","volume":"32","author":"McKinnon","year":"2018","journal-title":"BioDrugs"},{"key":"ref_388","unstructured":"European Biomedicines Agency (2026, July 22). Biosimilar Medicines Can Be Interchanged. Available online: https:\/\/www.ema.europa.eu\/en\/news\/biosimilar-medicines-can-be-interchanged."},{"key":"ref_389","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/s43441-025-00897-6","article-title":"Regulatory Requirements for Interchangeable Biosimilar Designation","volume":"60","author":"Samy","year":"2026","journal-title":"Ther. Innov. Regul. Sci."},{"key":"ref_390","doi-asserted-by":"crossref","unstructured":"Herndon, T.M., Ausin, C., Brahme, N.N., Schrieber, S.J., Luo, M., Andrada, F.C., Kim, C., Sun, W., Zhou, L., and Grosser, S. (2023). Safety outcomes when switching between biosimilars and reference biologics: A systematic review and meta-analysis. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0292231"},{"key":"ref_391","unstructured":"U.S. Food & Drug (2024). FDA Updates Guidance on Interchangeability."},{"key":"ref_392","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s11926-016-0601-0","article-title":"Pharmacoeconomics of Biosimilars: What Is There to Gain from Them?","volume":"18","author":"Fonseca","year":"2016","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_393","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s40259-024-00659-0","article-title":"Barriers and Enablers Affecting the Uptake of Biosimilar Medicines Viewed Through the Lens of Actor Network Theory: A Systematic Review","volume":"38","author":"Rieger","year":"2024","journal-title":"BioDrugs"},{"key":"ref_394","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00228-025-03819-5","article-title":"Facilitators and barriers to generic and biosimilar medications in the Middle East and North Africa: Insights from physicians and pharmacists\u2014A systematic review","volume":"81","author":"Alqawasmeh","year":"2025","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_395","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1248\/cpb.c25-00552","article-title":"Inhaled Biologics: Overcoming Challenges and Recent Advances","volume":"74","author":"Onoue","year":"2026","journal-title":"Chem. Pharm. Bull."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/8\/917\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:32:44Z","timestamp":1785299564000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/8\/917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,25]]},"references-count":395,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["pharmaceutics18080917"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics18080917","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,25]]}}}